Navigation Links
Avanir Pharmaceuticals Announces Presentation of Positive Early Results from PRISM II Study
Date:7/16/2014

tements regarding Avanir's plans, potential opportunities, financial or other expectations, projections, goals objectives, milestones, strategies, market growth, timelines, legal matters, product pipeline, clinical studies, product development and the potential benefits of its commercialized products and products under development are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the risks and uncertainties associated with, the market demand for and acceptance of Avanir's products domestically and internationally, research, development such as continued enrollment and data generation for the PRISM II study, and commercialization of new products domestically and internationally, obtaining additional indications for commercially marketed products domestically and internationally, obtaining and maintaining regulatory approvals domestically and internationally, and other risks detailed from time to time in the Company's most recent Annual Report on Form 10-K and other documents subsequently filed with or furnished to the Securities and Exchange Commission. These forward-looking statements are based on current information that may change and you are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and the Company undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.

Avanir Investor & Media Contact
Ian Clements, PhD
ir@avanir.com
+1 (949) 389-6700

Brewlife Media Contact
'/>"/>

SOURCE Avanir Pharmaceuticals, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Avanir Pharmaceuticals Pre-announces Preliminary Fiscal 2014 First Quarter Financial Information
2. Avanir Pharmaceuticals to Present at J.P. Morgan 32nd Annual Healthcare Conference
3. Quarterly Dividends, Clinical Trial Results, Dental Exhibition Updates, and Upcoming Presentation Schedules - Research Report Quest Diagnostics, Avanir, Sirona, Ligand and Genomic Health
4. Avanir Pharmaceuticals Reports Fiscal 2013 Fourth Quarter Financial and Year-End Business Results
5. Avanir Pharmaceuticals Announces Results for Phase II PRIME Study
6. Preliminary Financial Results, Quarterly Reports and Upcoming Conference Schedules - Research Report on Avanir, BioScrip, Chemed, Foundation Medicine, and Antares
7. Avanir Pharmaceuticals Pre-Announces Preliminary Fiscal 2013 Year End Financial Information
8. Avanir Pharmaceuticals to Host Investor Day on October 29, 2013
9. Avanir Pharmaceuticals Announces Enrollment of First Patient in Study of AVP-923 for the Treatment of Levodopa Induced Dyskinesia in Parkinsons Disease
10. Avanir Pharmaceuticals Announces Publication of AVP-825 Pharmacokinetic Data in Journal "Headache"
11. Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Wockhardt
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Colo. , Oct. 22, 2014   Surefire ... of infusion systems designed to maximize targeted delivery of ... pleased to announce that oncologist John R. Daniels ... Comprehensive Cancer Center, and surgical oncologist Steven C. ... have joined the Company,s Scientific Advisory Board (SAB).    ...
(Date:10/22/2014)... 2014 Sanomedics International Holdings, Inc. (OTCQB: SIMH) ... Research & Data Services, demand for thermometers is expected ... 2018, as demand for more accurate digital thermometers continues.  ... world,s largest market for thermometers, and one of the ... International Holdings, Inc. Sanomedics International Holdings designs, ...
(Date:10/22/2014)... AUSTIN, Texas , Oct. 22, ... today announced they have entered into a license ... designed to target cancers. PhosImmune possesses ... on the surfaces of tumor cells in association ... derived from proteins that play a role in ...
Breaking Medicine Technology:Surefire Medical's Scientific Advisory Board Expands, Broadens Clinical Trial Expertise 2Sanomedics International Holdings Analyst Report: Taking Some Heat by BrokerBank Securities, Inc. 2Biotech Companies To Co-Discover And Co-Develop Antibodies Targeting Novel Phosphopeptide Tumor Targets 2
... 2011 Advanced Life Sciences Holdings, ... cancelled its Annual Meeting of Shareholders, which was previously ...   (Logo:   http://photos.prnewswire.com/prnh/20080218/ALSLOGO ) ... Life Sciences is a biopharmaceutical company engaged in the ...
... N.Y., May 20, 2011 BioSpecifics Technologies Corp. ... developing first in class collagenase-based products, today provided ... (collagenase clostridium histolyticum) in Europe. As reported by ... is now available for sale by Pfizer, Inc. ...
Cached Medicine Technology:BioSpecifics Technologies Corp. Provides Update on XIAPEX® Launch Progress in EU 2BioSpecifics Technologies Corp. Provides Update on XIAPEX® Launch Progress in EU 3
(Date:10/22/2014)... 2014 Healthcare professionals who are ... education at home or on-the-go via laptops, tablets ... brand new, premium Seminar-on-Demand CE courses. The new ... 2,000 hours of CE course offerings, ... experience. With such a diverse library, there’s something ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 Akeso ... solutions for the treatment of bacterial infections, microbial biofilms, ... has joined its board of directors. , ... Engineering Systems at The Massachusetts Institute of Technology, or ... faculty since 1968. Dr. Sinskey also holds positions as ...
(Date:10/22/2014)... Maureen Salamon HealthDay ... A crucial part of conventional in vitro fertilization (IVF) -- ... instead take place in a device inside the vagina, new ... contend that the device, called an INVOcell, might sharply cut ... also make the technology more accessible to those who don,t ...
(Date:10/20/2014)... With a mere 19 days to November 4, ... fundraising stop at the  Law Offices of Dan ... debate last night with his opponent Gov. Rick Scott, ... seven minutes because Crist had an electric fan underneath ... one word: "weird." , Before touching on his well-known ...
(Date:10/20/2014)... T.E.N., a technology and information ... that William H. Murray, renowned author and industry ... Leadership Award winner. Presented annually, the ISE® Luminary ... leader and industry practitioner for his or her ... information security industry. , Formerly with IBM, Murray ...
Breaking Medicine News(10 mins):Health News:Top Provider of Continuing Education at Home Releases 20 New Online Courses 2Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 4Health News:At Crist Fundraiser, Dan Newlin Says, "No More Robert Germans," Will Seek Changes to Florida Missing Persons Law 2Health News:At Crist Fundraiser, Dan Newlin Says, "No More Robert Germans," Will Seek Changes to Florida Missing Persons Law 3Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 2Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 3Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 4
... that parents who share their beds// with their newborn babies can ... infant death syndrome or SIDS is one of the major reasons ... month to a year. SIDS is a disorder that seems to ... risk factors that seem to increase the incidence of SIDS. ...
... a common condition in India where beetle and tobacco chewing ... certain bacteria’s excessive presence may give an early warning of ... in the Open Access journal, Journal of Translational Medicine has ... squamous cell carcinoma) have six common species of bacteria in ...
... women and the condition// can sometimes be fatal. Now researcher ... basal ganglia region of the brain. ,People with ... unaware of the seriousness of their condition.When you talk of ... talented singer Karen Carpenter who died in the prime of ...
... blood to indicate the possibility of heart// attack in people ... issue of New England Journal of Medicine indicates that blood ... fatty build- up patients have in their arteries of ... use of invasive tests like angiograms. ,Oxidized phospholipids ...
... study by the researchers of University of British Columbia had ... help to our concentration and efficiency, more so when that ... balance. ,Noise is often thought as the one sensation ... want to concentrate upon. Noise is often related to the ...
... good for health, especially the role of fats, had been ... University had found out that the between the various kinds ... to have the healthy meal by banishing one kind of ... The right combination of both can help achieve the best ...
Cached Medicine News:Health News:PET Scan find the Area of Brain Responsible for Anorexia Nervosa 2Health News:PET Scan find the Area of Brain Responsible for Anorexia Nervosa 3
DS 5700 New Central Station...
... integrates drug infusion,with patient monitoring and ... modular platform. With multiple configuration,options, you ... you,need them, keeping the number of ... while managing the unique needs of,each ...
... Infusion System many of its innovations ... as the principles of human factors ... to the creation of a medical ... to reduce errors in operation while ...
... Essentris Critical Care, the world-class clinician documentation ... decades of focus on the specific needs ... care environments. Its broad, deep clinical functionality ... documentation and EMR solution in critical care, ...
Medicine Products: